XML 46 R31.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Investments (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2018
Investments [Abstract] |
Schedule of Cost Method Investments | Our cost-method investments are included in “Investments” in the condensed consolidated balance sheets and consist of our equity positions in the following privately-held companies (in thousands):
|  | June 30, 2018 |  | December 31, 2017
Respicardia Inc. (1) |  | $ | 17,705 |  |  | $ | 17,422 |
ImThera Medical, Inc. (2) |  | — |  |  | 12,900 |
Rainbow Medical Ltd. (3) |  | 1,140 |  |  | 1,172 |
MD Start II (4) |  | 1,164 |  |  | 1,199 |
Highlife S.A.S. (5) |  | 1,104 |  |  | — |
Other |  | 17 |  |  | 17 |
|  | $ | 21,130 |  |  | $ | 32,710 |
(1) | Respicardia Inc. (“Respicardia”) is a privately funded U.S. company developing an implantable device designed to restore a more natural breathing pattern during sleep in patients with central sleep apnea ("CSA") by transvenously stimulating the phrenic nerve. We have a loan outstanding to Respicardia with a carrying amount of $0.5 million, as of June 30, 2018, which is included in “Prepaid expenses and other current assets” in the condensed consolidated balance sheet.
(2) | On January 16, 2018, we acquired the remaining outstanding interests in ImThera. Refer to “Note 3. Business Combinations”.
(3) | Rainbow Medical Ltd. is a private Israeli venture capital company that seeds and grows companies developing medical devices in a diverse range of medical fields.
(4) | MD Start II is a private venture capital collaboration for the development of medical device technology in Europe.
(5) | Due to an additional investment by a third party during the three months ended June 30, 2018, our equity interest in Highlife S.A.S. (“Highlife”) decreased to 17.5% from 24.6%. We determined that we no longer had significant influence over Highlife and it is now considered a cost method investment. The carrying amount of our equity-method investment in Highlife was $1.8 million at December 31, 2017.

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition A tabular disclosure of (a) the aggregate carrying amount of all cost-method investments; (b) the aggregate carrying amount of cost-method investments that the investor did not evaluate for impairment for cost-method investments. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCostMethodInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration